Rédaction Africa Links 24 with Katie Palmer and Lizzy Lawrence
Published on 2024-03-05 23:41:19
Dexcom has made a significant stride in diabetes management with the recent FDA approval of their new continuous glucose monitor, the Stelo. This innovative product is set to revolutionize the way individuals with type 2 diabetes, who do not rely on insulin, monitor their blood sugar levels. Additionally, it appeals to those without diabetes who are interested in understanding how diet and exercise affect their glucose levels.
The Stelo works in conjunction with a smartphone app, providing users with blood glucose readings every 15 minutes. This real-time data allows individuals to make informed decisions about their lifestyle choices and better manage their health. Dexcom has not yet disclosed the pricing for the device, but considering the value it brings to the table, it is poised to be a game-changer in the market.
Continuous glucose monitoring technology has come a long way since its inception in 2017. Initially approved for people with type 1 diabetes, these devices have become indispensable in managing blood sugar levels effectively and non-invasively. For some users, CGMs are also integrated with insulin pumps for seamless control. Companies like Dexcom and Abbott have capitalized on this growing market, with CGM becoming a $5 billion industry.
The FDA’s decision to allow the sale of the Stelo without a prescription marks a significant milestone in diabetes care. It empowers individuals to take control of their health and monitor their glucose levels with ease. The accessibility of this technology opens up new possibilities for people who may not have had access to continuous glucose monitoring before. With the Stelo, anyone in the United States can now benefit from this life-changing technology.
As we look ahead to the summer launch of the Stelo, there is much anticipation surrounding its impact on the diabetes community. The ability to track blood sugar levels continuously and effortlessly through a smartphone app is a major step forward in diabetes management. This device has the potential to improve the quality of life for individuals with type 2 diabetes and provide valuable insights for those looking to optimize their health through proactive monitoring.
In conclusion, the FDA’s approval of the Dexcom Stelo represents a breakthrough in diabetes care. By making continuous glucose monitoring more accessible to a wider audience, Dexcom is empowering individuals to take charge of their health in a new and innovative way. With the launch of the Stelo this summer, we can expect to see positive outcomes for both individuals with diabetes and those seeking to enhance their overall well-being through real-time data tracking.
